Literature DB >> 33769373

Updated strategies in the management of acute variceal haemorrhage.

Jerome Edelson1, Jessica E Basso1, Don C Rockey2.   

Abstract

PURPOSE OF REVIEW: This article reviews the most recent studies regarding the management of acute esophageal variceal haemorrhage. RECENT
FINDINGS: New randomized control trials and meta-analyses confirmed the role of early transjugular intrahepatic portosystemic shunt (TIPS) in the management of acute variceal haemorrhage in Child-Pugh C (10-13) and B patients with active bleeding. A recent randomized controlled trial focused on the duration of vasoactive therapy showed no difference between 2 and 5 days of octreotide. A randomized trial showed decreased use of blood products for the correction of coagulopathy using a thromboelastography-guided approach (vs. conventional parameters) as well as decreased bleeding rates when compared with standard of care. A meta-analysis found that for rescue of variceal bleeding, self-expanding metallic stents were more efficacious and safer than balloon tamponade. In addition, studies showed that Child-Pugh C patients and those with hepatic vein pressure gradient more than 20 were at the highest risk of treatment failure, while model for end-stage liver disease was highly predictive of in-hospital mortality.
SUMMARY: In patients with severe coagulopathy and uncontrolled bleeding, TEG-based transfusion strategies are recommended. Antibiotics should be used for all cirrhotic patients presenting with upper gastrointestinal bleeding, but should be tailored in accordance to local resistance patterns. Early TIPS for high-risk patients has been shown to have a significant survival benefit. Certain aspects of the management of variceal bleeding remain poorly studied such as the role of early TIPS in Child-B patients as well as strategies for rescue therapy in patients who are not TIPS candidates, and require further investigation.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33769373      PMCID: PMC8691141          DOI: 10.1097/MOG.0000000000000723

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  40 in total

1.  Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.

Authors:  Javier Fernández; Verónica Prado; Jonel Trebicka; Alex Amoros; Thierry Gustot; Reiner Wiest; Carme Deulofeu; Elisabet Garcia; Juan Acevedo; Valentin Fuhrmann; François Durand; Cristina Sánchez; Maria Papp; Paolo Caraceni; Victor Vargas; Rafael Bañares; Salvatore Piano; Martin Janicko; Agustin Albillos; Carlo Alessandria; German Soriano; Tania M Welzel; Wim Laleman; Alexander Gerbes; Andrea De Gottardi; Manuela Merli; Minneke Coenraad; Faouzi Saliba; Marco Pavesi; Rajiv Jalan; Pere Ginès; Paolo Angeli; Vicente Arroyo
Journal:  J Hepatol       Date:  2018-11-02       Impact factor: 25.083

2.  Deleterious effect of proton pump inhibitors on the disease course of cirrhosis.

Authors:  Tamás Janka; Tamás Tornai; Brigitta Borbély; Dávid Tornai; István Altorjay; Mária Papp; Zsuzsanna Vitális
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-02       Impact factor: 2.566

3.  Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review.

Authors:  N C Chavez-Tapia; T Barrientos-Gutierrez; F Tellez-Avila; K Soares-Weiser; N Mendez-Sanchez; C Gluud; M Uribe
Journal:  Aliment Pharmacol Ther       Date:  2011-06-27       Impact factor: 8.171

Review 4.  Natural history of portal hypertension in patients with cirrhosis.

Authors:  R de Franchis; M Primignani
Journal:  Clin Liver Dis       Date:  2001-08       Impact factor: 6.126

5.  Different scoring systems to predict 6-week mortality in cirrhosis patients with acute variceal bleeding: a retrospective analysis of 202 patients.

Authors:  Fang Wang; Shu Cui; Fengmei Wang; Fenghui Li; Fei Tang; Xu Zhang; Yanying Gao; Hongmin Lv
Journal:  Scand J Gastroenterol       Date:  2018-06-17       Impact factor: 2.423

6.  Thromboelastography-guided Blood Product Transfusion in Cirrhosis Patients With Variceal Bleeding: A Randomized Controlled Trial.

Authors:  Gyanranjan Rout; Deepak Gunjan; Soumya J Mahapatra; Saurabh Kedia; Pramod K Garg; Baibaswata Nayak
Journal:  J Clin Gastroenterol       Date:  2020-03       Impact factor: 3.062

7.  Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy.

Authors:  Juan G Abraldes; Cándid Villanueva; Rafael Bañares; Carles Aracil; Maria Vega Catalina; Juan Carlos Garci A-Pagán; Jaime Bosch
Journal:  J Hepatol       Date:  2007-11-26       Impact factor: 25.083

8.  A MELD-based model to determine risk of mortality among patients with acute variceal bleeding.

Authors:  Enric Reverter; Puneeta Tandon; Salvador Augustin; Fanny Turon; Stefania Casu; Ravin Bastiampillai; Adam Keough; Elba Llop; Antonio González; Susana Seijo; Annalisa Berzigotti; Mang Ma; Joan Genescà; Jaume Bosch; Joan Carles García-Pagán; Juan G Abraldes
Journal:  Gastroenterology       Date:  2013-10-19       Impact factor: 22.682

9.  Risk stratification in acute variceal bleeding: Comparison of the AIMS65 score to established upper gastrointestinal bleeding and liver disease severity risk stratification scoring systems in predicting mortality and rebleeding.

Authors:  Marcus Robertson; Jonathan Ng; Walid Abu Shawish; Adrian Swaine; Gillian Skardoon; Andrew Huynh; Sheetal Deshpande; Zi Yi Low; William Sievert; Peter Angus
Journal:  Dig Endosc       Date:  2019-12-20       Impact factor: 7.559

10.  Outcomes of patients treated with Sengstaken-Blakemore tube for uncontrolled variceal hemorrhage.

Authors:  Ja Yun Choi; Yun Won Jo; Sang Soo Lee; Wan Soo Kim; Hye Won Oh; Cha Young Kim; Eun Young Yun; Jin Joo Kim; Jae Min Lee; Hong Jun Kim; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Rock Bum Kim
Journal:  Korean J Intern Med       Date:  2017-11-10       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.